Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the company’s stock with a ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler ...

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ.

Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

Investing.com - TD Cowen initiated coverage on Soleno Therapeutics Inc. (NASDAQ: SLNO) with a buy rating and a price target of $110.00 on Monday.The company, currently valued at $4.03 billion, has ...

TD Cowen analyst Tyler Van Buren initiated coverage of Soleno Therapeutics (SLNO) with a Buy rating and $110 price target The firm says Vykat XR ...

REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...